- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01019681
Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia
Umbilical Cord Blood Stem Cell Injection for Critical Limb Ischemia
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Umbilical cord blood is a safe alternative source of stem cells used for decades in hematopoietic stem cell transplants for malignancies. There is also a reported decreased incidence of acute GVHD compared to matched unrelated donor transplants.A cord blood registry will be searched for suitable units with compatibility in the ABO and HLA systems. The minimum total nucleated cell dose required which would be 1.0 x 107/kg, and one unit of cells will be procured to meet this requirement. Although it is likely that the transplanted cord blood cells will be rejected over time, we hypothesize that while they remain in the host's tissue these cells will be producing and releasing cytokines, growth factors and other humoral factors that might promote vasculogenesis by stimulating endogenous stem cells and endothelial cells. Since there is no need to collect the patient's own stem cells, the patient's cardiovascular system will not be subjected to any stress due to the leukapheresis procedure itself. No injections of exogenous growth factors, which have been associated with thrombosis, would be required to mobilize the patient's own stem cells. The procedure could conceivably even be performed in its entirety on an outpatient basis.
A total of 25 patients will be enrolled in the study. Patients will be followed for 24 months after the procedure with evaluation visits one day after the transplant and then at one month, six, twelve and twenty four months post-treatment. The visit one day after the transplant will involve a history and physical with a leg exam, a CBC and a chemistry panel to evaluate for possible infection, or other adverse event.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Atherosclerotic ischemic peripheral vascular disease or Thromboangiitis Obliterans with Critical Limb Ischemia (Fontaine stages III and IV)
Participant must match either a or b
- Ankle brachial index (ABI) ≤ 0.7
- Doppler waveforms at posterior tibial artery and dorsalis pedis artery are monophasic with toe pressure < 30 mmHg.
- A non-surgical candidate for revascularization e.g. prior vascular reconstruction, inability to locate a suitable vein for grafting, diffuse multi- segment disease, or extensive infra-popliteal disease not amenable to a vascular graft.
- Age > 18 years old.
- The non-index leg may be treated only in the event and it full fills the same eligibility criteria and exclusion criteria used in this protocol for the treatment leg.
- Patients must be on maximal tolerated medical therapy for PVD including A) Cessation of smoking B) Referral to endocrinologist for control of HgA1c to < 7.0 mg/dl, control of hyperlipidemia with statins or other anti-hyperlipidemic drugs as indicated, control of hypertension as indicated C) Antiplatelet therapy with aspirin and / or cilostazol (unless medically contraindicated, e.g. bleeding or allergy)
Exclusion Criteria:
- Popliteal vascular entrapment syndrome
- Lower extremity infection or infected ulcer
- Hypercoagulable state
- HIV positive
- HBsAg positive
- Uncontrolled arrhythmia, that is, persistence of an arrhythmia despite medical therapy
- Unstable angina
- Thrombocytopenia < 50,000/ul
- Leukemia or myelodysplasia
- Allergy to E coli or its products
- Patients with metal in their bodies cannot undergo MRIs (MRA). Therefore, patients with, cochlear implants, or aneurysm clips are not eligible. Coronary artery stents are not a contraindication. Patients with pacemakers are still candidates provided they have normal creatinine (< 1.1 mg/dl) and can receive contrast dye (no allergy) for angiogram instead of MRA. MRI/MRA does not need to be repeated if a prior MRA or Angiogram Demonstrates inoperable disease.
- Patients who are pregnant
- Poorly controlled diabetes will not be a cause for exclusion but patient must see endocrinologist for better control
- Current malignancy, except squamous cell or basal cell skin cancers thought to be easily controlled.
- AST, ALT, or bilirubin more than twice the upper limit of normal.
- WBC < 2.5 / ul.
- Any patient who is actively bleeding, including blood on urine dipstick or fecal occult blood.
- Patient is on chemotherapy or other immuno-suppressive medications such as steroids, cellcept, cyclosporine, cytoxan, azathioprine, rituxan, humira or remicade.
- Donor is HLA homozygous and shares that HLA haplotype with the recipient (a different donor will have to be found)
- Patients diagnosed with Thromboangiitis Obliterans (Buerger's Disease) who are smokers and are unwilling or unable to quit smoking
- A) Patients with a myocardial infarction within the last 30 days or left ventricular ejection fraction < 35% B) Patients with a history of malignancy in the last 5 years (other than basal cell carcinoma or carcinoma in situ) C) Patients with a CVA within the last 6 months D) Patients with a HbA1c level > 7.0%
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: UBC injection into one leg of PVD pt
25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.
|
The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure. Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois).
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Ankle brachial index (ABI), a 15% increase will be considered improvement
Časové okno: Pre-transplant, 1, 6, 12 and 24 months after
|
Pre-transplant, 1, 6, 12 and 24 months after
|
|
Healing of ischemic ulcers
Časové okno: Pre-transplant, 1, 6, 12 and 24 months after
|
Pre-transplant, 1, 6, 12 and 24 months after
|
|
Decreased pain level as reported by the patient
Časové okno: Pre-transplant, 1, 6, 12 and 24 months after
|
Pre-transplant, 1, 6, 12 and 24 months after
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
SF-36 quality of life (QOL)
Časové okno: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
|
Walking Impairment Questionnaire
Časové okno: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
|
Increase in pain free ambulation time on treadmill by more than 25%
Časové okno: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
|
Increase in four meter walk or six minute walk by more than 25%
Časové okno: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Richard Burt, MD, Northwestern University and Northwestern Memorial Hospital
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- PVD.Cord.Blood.2008
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Ischemie kritické končetiny
-
Attikon HospitalUniversity Hospital of PatrasDokončeno
-
IPERF SASEuropean Cardiovascular Research CenterNábor
-
Kafrelsheikh UniversityZápis na pozvánku
-
Meshalkin Research Institute of Pathology of CirculationNáborAteroskleróza | Ischemia Limb | Okluze povrchové femorální tepny | Okluze popliteální tepny | Komplikace stentuRuská Federace
-
Kolding SygehusNeznámýKvalita života | Ischemia Limb | Komplikace rány | Kompresní terapie | Pooperační edémDánsko
-
Meshalkin Research Institute of Pathology of CirculationNáborAteroskleróza | Ischemia Limb | Okluze povrchové femorální tepny | Okluze popliteální tepnyRuská Federace
-
Otivio ASHannover Medical School; mediq Innovation Experts GmbHUkončenoIntermitentní klaudikace | Onemocnění periferních cév | Ischemia Limb | Ischemie kritické končetiny | Chůze, ObtížnostNěmecko
-
Oslo University HospitalSensocure ASZatím nenabírámeIschemia Limb | Kompartment syndrom nohy | Oxid uhličitý | Porucha krevního oběhu | Biosnímací technikyNorsko
-
Unity Health TorontoDefence Research and Development CanadaNeznámýCOVID | Ischemia Limb | Syndrom akutní dechové tísně | Akutní poranění plic | Koronavirová infekce
Klinické studie na Cord blood stem cell injection
-
National Marrow Donor ProgramDokončenoLymfom | Myelodysplastické syndromy | LeukémieSpojené státy
-
Jiangsu Renocell Biotech CompanyZatím nenabírámeSystémová skleróza
-
Beijing Boren HospitalUkončenoPokročilý pevný nádor | Recidivující/refrakterní lymfomČína
-
Imbioray (Hangzhou) Biomedicine Co., Ltd.The First Affiliated Hospital of Soochow UniversityZatím nenabíráme
-
Imbioray (Hangzhou) Biomedicine Co., Ltd.Nábor
-
Nanjing Bioheng Biotech Co., Ltd.NáborStudie anti-CD19/BCMA Universal Car-T buněčné terapie RD06-05 u pacientů s autoimunitními chorobami.SLE | Vaskulitida spojená s ANCA | MN | LN | SSc | Glomerulonefritida spojená s ANCA | IIM | Anti-GBM nemocČína
-
The First Affiliated Hospital with Nanjing Medical...Zatím nenabírámeRecidivující nebo refrakterní hematologické malignity
-
BHI Therapeutic SciencesNeznámýAkutní ischemická mrtviceSpojené státy
-
Novabio TherapeuticsThe First Affiliated Hospital of Zhengzhou UniversityNáborAmyotrofická laterální skleróza (ALS)Čína